Humana raises FY2022 adjusted EPS guidance to ~$25, introduces 2025 adjusted EPS target of $37

HUMANA INC

Brad D. Smith (former Intuit CEO, now president of Marshall University) elected to Board effective Sept 15, 2022; board expands to 14.
FY2022 GAAP EPS guidance raised to ~$23.08 from ~$20.30; adjusted EPS raised to ~$25.00 from ~$24.75, reflecting 21% YoY growth.
Mid-term adjusted EPS target of $37.00 for 2025, representing ~14% CAGR over updated FY2022 outlook.
Guidance driven by lower-than-expected medical cost trends and no material COVID-19 headwind; company released $0.50 COVID reserve.
Company expects continued earnings growth in 2026 and beyond at or above trends reflected in mid-term target.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brad D. Smith

director

HUM · HUMANA INC

Effective: 2022-09-15
Filed: September 15, 2022, 7:59 PM ET

Effective September 15, 2022, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from thirteen to fourteen and elected Brad D. Smith as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brad D. Smith was elected as director at HUMANA INC.

Action: elected
Role: director

Exact text from the filing

Effective September 15, 2022, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from thirteen to fourteen and elected Brad D. Smith as a director of the Company.

View on SEC.gov

HUMANA INC filing history →

Source: SEC EDGAR

accession 0000049071-22-000060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.